Creative Biolabs Launches Neuroscience Antibody Tools Targeting Key Disease Mechanisms
TL;DR
Creative Biolabs' new antibody products for GRID2, TH, and ACTN3 research give scientists a competitive edge in developing targeted neurological treatments and muscle disorder therapies.
Creative Biolabs provides specific antibodies that enable researchers to systematically study synaptic proteins, neurotransmitter synthesis, and muscle genetics through established methods like Western blot and immunohistochemistry.
These research tools advance understanding of neurological diseases and muscle disorders, potentially leading to better treatments that improve quality of life for patients worldwide.
Discover how Creative Biolabs' antibody products help researchers map synaptic function and muscle genetics, revealing fascinating connections between molecular biology and human movement.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs has introduced a suite of antibody tools targeting critical neuroscience proteins, addressing the growing global burden of neurodegenerative diseases, movement disorders, and psychiatric conditions. The company's new products focus on three key molecular targets: GRID2 for synaptic function research, tyrosine hydroxylase for neurotransmitter studies, and ACTN3 for muscle genetics investigations.
The GRID2 gene has emerged as a significant focus in neurological research, with mutations linked to cerebellar ataxia and learning deficits. Research demonstrates that GRID2 plays a dominant role in motor coordination and synaptic transmission. In disease models, abnormal GRID2 expression reflects molecular mechanisms of neural circuit imbalance and provides rationale for targeted interventions. Creative Biolabs offers Rabbit Anti-GRID2 Recombinant Antibody and Mouse Anti-GRID2 Recombinant Antibody, applicable in ELISA, flow cytometry, Western blotting, and immunohistochemistry. These highly specific products enable researchers to accurately study spatial characteristics and dynamic regulation of synaptic proteins.
Tyrosine hydroxylase represents another critical target as the rate-limiting enzyme in catecholamine synthesis, catalyzing the conversion of L-tyrosine to L-DOPA, which subsequently produces dopamine, norepinephrine, and epinephrine. This enzyme is particularly important in Parkinson's disease research, where changes in TH levels reflect the functional state of dopaminergic neurons. The company provides Mouse Anti-Tyrosine Hydroxylase Recombinant Antibody (AV1), optimized for Western blot and immunohistochemistry applications to sensitively capture molecular changes along neurotransmitter synthesis pathways.
Beyond neurotransmitter and synaptic function research, Creative Biolabs addresses genetic regulation in the motor system through ACTN3-targeted tools. The ACTN3 gene encodes α-actinin-3, a critical protein for maintaining structural integrity and explosive power of fast-twitch muscle fibers. The company offers Mouse Anti-ACTN3 Recombinant Antibody for IHC and WB applications, along with Rabbit Anti-ACTN3 Recombinant Antibody suitable for WB, IH, IC, and Flow cytometry studies. These tools support research in sports genetics, muscle disorders, and personalized training.
The development of these specialized antibody tools comes as neurological disorders continue to represent a significant global health challenge. With neurodegenerative diseases affecting millions worldwide and Parkinson's disease prevalence increasing, the availability of precise research tools becomes increasingly critical for advancing therapeutic development. These antibody products enable researchers to generate clearer molecular maps within cell and animal model systems, potentially accelerating the discovery of new treatment approaches and neuroprotective strategies.
Curated from 24-7 Press Release
